BRPI0805826A2 - compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento - Google Patents
compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento Download PDFInfo
- Publication number
- BRPI0805826A2 BRPI0805826A2 BRPI0805826-1A BRPI0805826A BRPI0805826A2 BR PI0805826 A2 BRPI0805826 A2 BR PI0805826A2 BR PI0805826 A BRPI0805826 A BR PI0805826A BR PI0805826 A2 BRPI0805826 A2 BR PI0805826A2
- Authority
- BR
- Brazil
- Prior art keywords
- spiro
- pharmaceutical composition
- production method
- treatment methods
- angiogenesis inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTOS ESPIRO-SUBSTITUìDOS COMO INIBIDORES DE ANGIOGENESE, MéTODO DE PRODUçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODOS DE TRATAMENTO. Trata-se a presente invenção de compostos espiro-substituídos (Tetracarbon) da Fórmula I, bem como dos processos para sua preparação, de composições farmacêuticas contendo os ditos compostos como o ingrediente ativo, métodos para o tratamento de estados patológicos associados à angiogênese, como, por exemplo, cânceres associados à proteína tirosina quinases, bem como sua utilização como medicamentos para serem utilizados na produção de inibição de proteína tirosina quinases, reduzindo os efeitos em animais de sangue quente, como, por exemplo, em seres humanos.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89469207P | 2007-03-14 | 2007-03-14 | |
| US60/894,692 | 2007-03-14 | ||
| US94169807P | 2007-06-04 | 2007-06-04 | |
| US60/941,698 | 2007-06-04 | ||
| US12/036,244 | 2008-02-23 | ||
| US12/036,244 US8148532B2 (en) | 2007-03-14 | 2008-02-23 | Spiro substituted compounds as angiogenesis inhibitors |
| PCT/US2008/054816 WO2008112407A1 (en) | 2007-03-14 | 2008-02-24 | Spiro substituted compounds as angiogenesis inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0805826A2 true BRPI0805826A2 (pt) | 2011-08-30 |
| BRPI0805826B1 BRPI0805826B1 (pt) | 2021-02-09 |
| BRPI0805826B8 BRPI0805826B8 (pt) | 2021-05-25 |
Family
ID=39759893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0805826A BRPI0805826B8 (pt) | 2007-03-14 | 2008-02-24 | compostos espiro-substituídos, composição farmacêutica e uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8148532B2 (pt) |
| EP (1) | EP2125776B1 (pt) |
| JP (1) | JP5522371B2 (pt) |
| KR (1) | KR101514469B1 (pt) |
| CN (4) | CN101809012B (pt) |
| AU (1) | AU2008226666B2 (pt) |
| BR (1) | BRPI0805826B8 (pt) |
| CA (1) | CA2709220C (pt) |
| DK (1) | DK2125776T3 (pt) |
| ES (1) | ES2643619T3 (pt) |
| IL (1) | IL200934A0 (pt) |
| MX (1) | MX2009008953A (pt) |
| NZ (1) | NZ579389A (pt) |
| PL (1) | PL2125776T3 (pt) |
| PT (1) | PT2125776T (pt) |
| WO (1) | WO2008112407A1 (pt) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| CN103664892B (zh) * | 2010-08-01 | 2015-09-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| CN103664890B (zh) * | 2010-08-01 | 2016-10-05 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及制备方法 |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| JP6026441B2 (ja) | 2011-03-04 | 2016-11-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としてのアミノキノリン |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| WO2014032019A2 (en) * | 2012-08-23 | 2014-02-27 | Georgetown University | Compounds and methods of use thereof for treating tumors |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| EP2945931A4 (en) * | 2013-01-18 | 2016-10-12 | Advenchen Pharmaceuticals Llc | PROCESS FOR THE PREPARATION OF ANTITUMOR AGENT, 6- (7 - ((1-AMINO-CYCLO-PROPYL) -METHOXY) -6-METHOXYQUINOLIN-4-YLOXY) -N-METHYL-1-NAPHTHAMIDE, AND His crystalline form |
| US9695184B2 (en) * | 2013-02-15 | 2017-07-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9353123B2 (en) * | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN105143208B (zh) | 2013-02-21 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的喹唑啉 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
| EP3169687B1 (en) | 2014-07-14 | 2019-01-02 | Advenchen Pharmaceuticals, Nanjing Ltd. | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
| CN114767680A (zh) * | 2014-12-09 | 2022-07-22 | 正大天晴药业集团股份有限公司 | 治疗非小细胞肺癌的喹啉衍生物 |
| AU2015360095B2 (en) * | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| CN106999485B (zh) * | 2014-12-09 | 2020-04-14 | 正大天晴药业集团股份有限公司 | 抗肺鳞癌的喹啉衍生物 |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| EP3319602B1 (en) | 2015-07-11 | 2020-02-05 | Advenchen Pharmaceuticals LLC | Fused quinoline compounds as pi3k/mtor inhibitors |
| WO2017035114A1 (en) | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN115025090A (zh) * | 2016-01-08 | 2022-09-09 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| CN107778288B (zh) * | 2016-08-26 | 2020-07-28 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法和用途 |
| CN107778290B (zh) * | 2016-08-30 | 2020-07-24 | 正大天晴药业集团股份有限公司 | 一种喹啉衍生物的杂质及其制备方法 |
| CN110650741A (zh) * | 2017-05-26 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的喹啉衍生物 |
| CN109422731A (zh) * | 2017-08-24 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代喹啉衍生物 |
| WO2019052520A1 (zh) | 2017-09-15 | 2019-03-21 | 正大天晴药业集团股份有限公司 | 用于治疗神经内分泌肿瘤的喹啉衍生物 |
| CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
| CN114716410A (zh) * | 2018-02-11 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| CN111936467B (zh) | 2018-03-02 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途 |
| US11419862B2 (en) | 2018-03-14 | 2022-08-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of nasopharyngeal carcinoma |
| CN115487188B (zh) * | 2018-03-14 | 2024-05-14 | 正大天晴药业集团股份有限公司 | 治疗鼻咽癌的喹啉衍生物 |
| US11554115B2 (en) * | 2018-03-14 | 2023-01-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of triple-negative breast cancer |
| CN110339195A (zh) * | 2018-04-02 | 2019-10-18 | 正大天晴药业集团股份有限公司 | 用于治疗胆管癌的喹啉衍生物 |
| CN110357856B (zh) * | 2018-04-09 | 2021-02-26 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
| CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
| CN116440134A (zh) * | 2018-05-22 | 2023-07-18 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
| CN110577546B (zh) * | 2018-06-08 | 2021-09-07 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
| WO2019233458A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr抑制剂及其制备方法和应用 |
| EP3816161A4 (en) | 2018-06-25 | 2022-03-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CRYSTALLINE FACIES OF A QUINOLINE DERIVATIVE AND METHOD FOR PREPARING A CRYSTALLINE POWDER THEREOF |
| CN116077647B (zh) | 2018-07-18 | 2025-06-27 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN115850237B (zh) * | 2018-07-24 | 2025-03-28 | 正大天晴药业集团股份有限公司 | 一种吲哚衍生物的合成方法 |
| CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
| WO2020029918A1 (zh) * | 2018-08-06 | 2020-02-13 | 正大天晴药业集团股份有限公司 | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 |
| SG11202102682SA (en) | 2018-09-18 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Quinoline derivative used for treating small cell lung cancer |
| CN112996784B (zh) * | 2018-09-18 | 2023-05-30 | 北京越之康泰生物医药科技有限公司 | 吲哚衍生物及其在医药上的应用 |
| CN109705093A (zh) * | 2018-12-29 | 2019-05-03 | 正大天晴药业集团股份有限公司 | 喹啉衍生物及其制备方法和用途 |
| CN118267468A (zh) | 2019-01-25 | 2024-07-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| CN109748904A (zh) | 2019-01-31 | 2019-05-14 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| CN111617243B (zh) * | 2019-02-28 | 2023-12-19 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN117797151A (zh) * | 2019-03-04 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 |
| CN111643503A (zh) * | 2019-03-04 | 2020-09-11 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的喹啉衍生物 |
| CN111714498A (zh) * | 2019-03-20 | 2020-09-29 | 正大天晴药业集团股份有限公司 | 用于治疗卵巢癌的喹啉衍生物 |
| KR20220003560A (ko) | 2019-04-19 | 2022-01-10 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염 |
| CN111840289A (zh) * | 2019-04-28 | 2020-10-30 | 正大天晴药业集团股份有限公司 | 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐 |
| US12377089B2 (en) | 2019-05-10 | 2025-08-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative used for soft tissue sarcoma combination therapy |
| CN113747897B (zh) | 2019-05-10 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体联合治疗软组织肉瘤 |
| CA3141174A1 (en) * | 2019-05-23 | 2020-11-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivatives for treatment of head and neck cancer |
| EP4008730A4 (en) | 2019-08-02 | 2023-09-06 | Akeso Pharmaceuticals, Inc. | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES |
| BR112022002028A2 (pt) | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| EP4056200A4 (en) | 2019-11-04 | 2024-01-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MEDICINAL COMBINATION OF QUINOLINE DERIVATIVE AND MONOCLONAL PD-1 ANTIBODY |
| CN114929225B (zh) * | 2020-01-19 | 2024-06-28 | 正大天晴药业集团股份有限公司 | 用于治疗类风湿性关节炎的喹啉衍生物 |
| CN113262223A (zh) * | 2020-02-17 | 2021-08-17 | 上海交通大学医学院 | 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用 |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
| CN111888358A (zh) * | 2020-08-24 | 2020-11-06 | 天津济坤医药科技有限公司 | 安罗替尼在制备用于治疗肝纤维化疾病的药物中的应用 |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2024180476A1 (en) | 2023-02-27 | 2024-09-06 | Assia Chemical Industries Ltd. | Solid state forms of anlotinib and process for preparation thereof |
| AU2024411090A1 (en) | 2023-12-28 | 2026-07-16 | Fortvita Biologics (Singapore) Pte. Ltd. | Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof |
| CN120154618B (zh) * | 2025-05-15 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 格索雷塞用于治疗肺癌的用途或其药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| EP1660503A1 (en) | 2003-08-29 | 2006-05-31 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| WO2005044302A1 (en) * | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| AP2006003619A0 (en) * | 2003-12-23 | 2006-06-30 | Pfizer | Novel quinoline derivatives |
| US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
| WO2005070891A2 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| WO2005097137A2 (en) | 2004-03-31 | 2005-10-20 | The Scripps Research Institute | Advanced quinazoline based protein kinase inhibitors |
| US20080268460A1 (en) | 2004-05-20 | 2008-10-30 | Wyeth | Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases |
| KR100735639B1 (ko) * | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
-
2008
- 2008-02-23 US US12/036,244 patent/US8148532B2/en active Active
- 2008-02-24 CN CN200880007358XA patent/CN101809012B/zh active Active
- 2008-02-24 CA CA2709220A patent/CA2709220C/en active Active
- 2008-02-24 CN CN201310454117.2A patent/CN103483319B/zh active Active
- 2008-02-24 CN CN201610147579.3A patent/CN105837559B/zh active Active
- 2008-02-24 CN CN201310454104.5A patent/CN103467454B/zh active Active
- 2008-02-24 NZ NZ579389A patent/NZ579389A/en not_active IP Right Cessation
- 2008-02-24 EP EP08730589.2A patent/EP2125776B1/en active Active
- 2008-02-24 PL PL08730589T patent/PL2125776T3/pl unknown
- 2008-02-24 MX MX2009008953A patent/MX2009008953A/es active IP Right Grant
- 2008-02-24 PT PT87305892T patent/PT2125776T/pt unknown
- 2008-02-24 JP JP2009553672A patent/JP5522371B2/ja active Active
- 2008-02-24 ES ES08730589.2T patent/ES2643619T3/es active Active
- 2008-02-24 BR BRPI0805826A patent/BRPI0805826B8/pt active IP Right Grant
- 2008-02-24 AU AU2008226666A patent/AU2008226666B2/en not_active Ceased
- 2008-02-24 WO PCT/US2008/054816 patent/WO2008112407A1/en not_active Ceased
- 2008-02-24 DK DK08730589.2T patent/DK2125776T3/en active
- 2008-02-24 KR KR1020097016377A patent/KR101514469B1/ko active Active
-
2009
- 2009-09-14 IL IL200934A patent/IL200934A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN101809012A (zh) | 2010-08-18 |
| BRPI0805826B8 (pt) | 2021-05-25 |
| EP2125776B1 (en) | 2017-07-05 |
| JP2010521473A (ja) | 2010-06-24 |
| KR101514469B1 (ko) | 2015-04-22 |
| AU2008226666A1 (en) | 2008-09-18 |
| CA2709220A1 (en) | 2008-09-18 |
| CN105837559B (zh) | 2019-11-29 |
| CN103467454B (zh) | 2016-05-04 |
| IL200934A0 (en) | 2010-05-17 |
| KR20090129985A (ko) | 2009-12-17 |
| NZ579389A (en) | 2012-04-27 |
| EP2125776A1 (en) | 2009-12-02 |
| PL2125776T3 (pl) | 2017-12-29 |
| ES2643619T3 (es) | 2017-11-23 |
| PT2125776T (pt) | 2017-10-04 |
| JP5522371B2 (ja) | 2014-06-18 |
| AU2008226666B2 (en) | 2013-10-03 |
| CA2709220C (en) | 2016-07-19 |
| CN105837559A (zh) | 2016-08-10 |
| MX2009008953A (es) | 2009-12-18 |
| US20080227811A1 (en) | 2008-09-18 |
| CN103483319A (zh) | 2014-01-01 |
| BRPI0805826B1 (pt) | 2021-02-09 |
| DK2125776T3 (en) | 2017-10-23 |
| WO2008112407A1 (en) | 2008-09-18 |
| CN103483319B (zh) | 2015-10-14 |
| EP2125776A4 (en) | 2011-06-22 |
| CN101809012B (zh) | 2013-11-27 |
| CN103467454A (zh) | 2013-12-25 |
| US8148532B2 (en) | 2012-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BRPI0808764B8 (pt) | compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica | |
| BRPI0912475B8 (pt) | compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| BR112013028430A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto | |
| BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
| BRPI0914927B8 (pt) | composto, composição farmacêutica e uso de um composto | |
| SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
| BRPI0718803B8 (pt) | composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula | |
| BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
| NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
| CU20100062A7 (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| NO20071776L (no) | Kinoksaliner som B RAF inhibitorer. | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| AR063628A1 (es) | Compuestos de piridinona utiles para el tratamiento de cancer | |
| BR112013006953A2 (pt) | composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença | |
| BRPI0709680B8 (pt) | derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase | |
| BR112013026834A2 (pt) | composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |